Drug intelligence / Profile preview

GSP15002

Development stage: Unknown
Lead developer: Green Sky Labs

Overview

GSP15002 is an investigational drug candidate developed by Green Sky Labs for the treatment of Amyotrophic Lateral Sclerosis (ALS). Although specific details regarding its molecular target, modality, and mechanism of action are not publicly disclosed, Green Sky Labs is a biotechnology company primarily focused on the development of cannabinoid-based therapies and advanced extraction technologies. The candidate has been documented in the company's pipeline as being in Phase 3 development for ALS.

Beyond the preview

Go deeper on GSP15002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSP15002.

Explore the full profile